focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Just imagine.....
The covid vaccines in a pill format.....
Every time a new strain appears, your local G.P. surgery / pharmacy issues a pill to you by post.
It would be easy to keep up and keep safe.
How much is that worth ???
OH....
And how low is the Mcap here now !!!
Imagine a tie in with Pfizer and Moderna.
What would that do for a company with an Mcap of only £13 Million ??
This is so cheap now....
A few more shares in issue, ok....
And probably around £3.5M in cash in the bank to progress work with.
From 09 /12 / 2020…. RNS Number : 3517H
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines”.
From 03 / 12 / 2020 RNS…. RNS Number : 3517H
Nigel Theobald, Chief Executive of N4 Pharma, commented:
we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.
And…. “ move towards collaborations."
Hmmmm…..
The plot Thickens………. Link them together ????
Massive news from N4P...... The ability to use its Nuvec silicon nanoparticles to store freeze dried plasmid DNA for up to 14 days at room temperature without loss of functionality is great news in potentially helping to practically deliver vaccines........
This share spiked up to 15p just under a week ago.
We now are almost half that price !!
But.......
We have....
An extra £2M in cash.
A product that the world needs desperatley.
Possible colaborations with major Pharma Co's.....
Silly low Mcap and not many shares in issue.
Oh.... And the overhang has just dried up.
>>>> ££££
Massive agreement with Lloyds bank.......
TruFin is pleased to announce that Satago has entered into a commercial pilot with Lloyds Bank, whereby the Bank will license Satago's software platform for its customers seeking single invoice finance solutions.
Imagine a tie in with Pfizer and Moderna.
What would that do for a company with an Mcap of only £13 Million ??
This is so cheap now....
A few more shares in issue, ok....
And probably around £3.5M in cash in the bank to progress work with.
From last RNS…. RNS Number : 3517H
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines”.
From todays RNS….
Nigel Theobald, Chief Executive of N4 Pharma, commented:
we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.
And…. “ move towards collaborations."
Hmmmm…..
The plot Thickens………. Link them together ????